The aptamer–siRNA conjugates: reprogramming T cells for cancer therapy
Harnessing the body’s own immune system has the potential to generate diverse, yet highly specific antitumor responses with protective long-term effects. Recent clinical advances demonstrated that new cancer immunotherapies can achieve impressive therapeutic effects, even in patients with advanced tumors of various types [1]. The rapid progress in this area was enabled by our improved understanding of the mechanisms underlying tumor immune evasion. Cancers evolved multiple strategies to block the activity of T lymphocytes and adaptive immune responses.
Click here to view the full article